Research Article

Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer

Chiranjeevi Padala1, Mohini Aiyengar Tupurani1, Kaushik Puranam1, Srilatha Gantala1, Nivas Shyamala1, Mrudula Spurthi Kondapalli1, Kishore kumar Gundapaneni1, Saraswati Mudigonda1, Rajesh Kumar Galimudi1, Keerthi Kupsal1, Santoshi Rani Nanchari1, Uday Chavan2, Sanjeeva kumari Chinta2, Srinivasulu Mukta2, Vishnupriya Satti1, Surekha Rani Hanumanth1*

1 Department of Genetics, Osmania University, Hyderabad, Telangana State, India, 2 MNJ Institute of Oncology & Regional Cancer Centre, Red Hills, Hyderabad, Telangana State, India

* surekharanih@gmail.com

Abstract

Background
Extracellular matrix degradation by matrix metalloproteinases (MMPs) is an important mechanism involved in tumor invasion and metastasis. Genetic variations of MMPs have shown association with multiple cancers. The present study is focused to elucidate the association of MMP-1, 3 and 9 genetic variants with respect to epidemiological and clinicopathological variables by haplotype, LD, MDR, survival in silico analyses among South Indian women.

Material and methods
MMP3–1171 5A/6A and MMP9–1562 C/T SNPs were genotyped by Allele specific polymerase chain reaction and MMP1-1607 1G/2G polymorphism by restriction fragment length polymorphism assays respectively, in 300 BC patients and age-matched 300 healthy controls. Statistical analysis was performed using the SNPStats and SPSS software. Linkage disequilibrium and gene-gene interactions were performed using Haploview and MDR software respectively. Further, transcription factor binding sites in the promoter regions of SNPs under study were carried out using AliBaba2.1 software.

Results
We have observed an increased frequency of 2G-allele of MMP1, 6A-allele of MMP3 and T-allele of MMP9 (p<0.05) respectively in BC subjects. The 2G-6A haplotype (minor alleles of MMP-1 and MMP-3 respectively) has shown an increased susceptibility to BC. Further, MMP polymorphisms were associated with the clinical characteristics of BC patients such as steroid hormone receptor status, lymph node involvement and metastasis. SNP combinations were in perfect LD in controls. MDR analysis revealed a positive interaction between
the SNPs, 5-years survival rate and cox-regression analysis showed a significant association with clinicopathological variables.

Conclusion

Our results suggest that MMP1–1607 1G/2G, MMP3–1171 5A/6A and MMP9–1562 C/T gene polymorphisms have synergistic effect on breast cancer. The interactions of MMPs clinical risk factors such as lymph node involvement has shown a strong correlation and might influence the 5-years survival rate, suggesting their potential role in the breast carcinogenesis.

Introduction

Breast Cancer (BC) is the most common cancer and a leading cause of death in women worldwide and in India. It is a multi-factorial, polygenic disease resulting from the interplay of genetic, epigenetic, environmental and lifestyle factors [1]. The breast microenvironment composed of extracellular matrix (ECM), stromal cells including endothelial and immune cells, fibroblasts and adipocytes playing a crucial role in mammary duct morphogenesis. Key enzymes regulating ECM turnover are matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) [2].

The matrix metalloproteinases are a family of secreted Zn-dependent endopeptidases playing an important role in the physiological processes and its deregulation is associated with various diseases including cancers [3]. The deregulated MMPs results in cancer progression such as cell proliferation, angiogenesis, invasion [4], metastasis and escape from the immune surveillance [5–6]. Activation of MMPs can be controlled by proteolytic enzymes such as plasmin, while their inhibition is controlled by their specific endogenous TIMPs [7].

MMPs are broadly divided into collagensases (MMP1), stromelysins (MMP3), gelatinases (MMP9) and membrane-associated-MMPs on the basis of their substrate specificity. Collagenases include MMP1, one of the most widely expressed MMP and can degrade type I, II, and III collagens. Stromelysins include MMP-3 an enzyme capable of degrading laminin, fibronectin, gelatins of type I, III, IV, and V; collagen and cartilage proteoglycans [8]. Gelatinase-B or MMP9 digest gelatins or denatured collagens [9].

The progress in the knowledge about the role of MMPs and their inhibitors in tumourigenesis have led to numerous studies which have tested a potential association of single nucleotide polymorphisms (SNPs) in these genes with cancer susceptibility and progression [10,11]. Although research has been performed to explore the role of SNPs of these genes in breast cancer individually [12–16], the results are inconclusive. Therefore, the present study has been performed to derive a more precise estimation of the association of MMPs and to elucidate the synergistic effect of genetic polymorphisms in the regulatory regions of MMP1 (rs1799750), MMP3 (rs35068180) and MMP9 (rs3918242) for susceptibility and progression of breast cancer by analysis of SNPs, haplotypes, LD, MDR, survival and in silico analysis along with epidemiological and clinicopathological variables in South Indian women.
Materials and methods

Ethics statement

This case-control study was carried out with the approval of the Ethics Committee of Mehdi Nawaj Jung (MNJ) Institute of Oncology & Regional Cancer Centre, Hyderabad, Telangana State, INDIA. The subject recruitment and sample collection were done only after obtaining written informed consent from the participants.

Study subjects

The present study consists of 300 confirmed breast cancer patients and 300 healthy controls from South India. Patients with breast cancer were consecutively recruited from MNJ regional cancer center, Hyderabad and women with any other cancer or other systemic inflammatory disease were excluded from the case and control group. Patients were enrolled from the department of oncology between the period from August 2011 to August 2016. Selection criteria for cases included patients who were histopathologically confirmed as breast cancer by medical and surgical oncologists. The patients were subjected to detailed demographical, clinical and pathological investigations. Staging of cancer was documented according to the AJCC-TNM classification system.

During the same time the control group was drawn from the same region with similar socio-economic status and the individuals included had no evidence of any personal history of cancer or other malignant conditions. General health history of the controls was collected with an appropriately designed proforma.

Data collection

A detailed description of the baseline characteristics of the breast cancer patients and healthy controls is shown in Table 1.

Clinical profile of breast cancer was evaluated with the help of medical and surgical oncologists according to the Union for International Cancer Control (UICC) and tumor–node metastasis (TNM) classification for breast cancer (WHO) and the same was noted in the case proforma from the tumor registries as shown in Table 2. [17].

Genomic DNA extraction

From each subject 4ml of blood was drawn into vaccutainer tubes containing ethylene-diamine-tetra-acetic acid (EDTA) and stored at 4°C. Genomic DNA was extracted from the whole blood sample by using non-enzymatic salting out method [18].

Genotyping

The promoter SNPs (Single nucleotide polymorphisms) in the MMP1, MMP3 and MMP9 genes were genotyped using PCR-RFLP (Restriction Fragment Length Polymorphism) method and AS-PCR (Allele Specific-Polymerase Chain Reaction) assays [16,19,20].

For confirmation, genotyping was performed without the knowledge of subjects case/control status. Furthermore, in order to ensure the accuracy of the genotyping data, our data was confirmed by Sanger sequencing analysis and the results were found to be in 100% concordance.
Statistical analysis

The continuous variables are expressed as the mean ± standard deviation (Mean±SD). Chi-square test for goodness-of-fit was used to analyze the difference in the frequency distribution between cases and controls for discontinuous variables. Hardy-Weinberg equilibrium test was performed between controls and patients for each SNP. The allele and genotype frequencies for all the polymorphisms were calculated using Chi-Square test for significance of differences between cases and controls. Adjusted odds (AOR) ratios were calculated by adjusting covariates such as age and haplotype frequencies were estimated in controls and cases using SNPStats [21]. Linkage disequilibrium (LD) plots of controls and cases were generated using Haploview program [22]. Gene–gene interactions were determined by MDR analysis [23]. We have also compared the allele and genotype distribution for all clinical and histopathological characteristics of cases. The p-values <0.05 were considered statistically significant.

The Kaplan-Meier survival analysis was carried out on the follow up data available from 216 breast cancer cases, taking death as an event occurring within 5 years of diagnosis to calculate median 5-years survival (OS) rate. The multivariate analysis of the probable predictive factors for survival was carried out using Cox’s proportional hazard regression analysis.

In silico analysis

The SNPs in the promoter regions of MMP-1, -3 and -9 genes were studied for the presence of transcription factor binding sites using AliBaba2.1 online tool (http://www.gene-regulation.com/pub/programs/alibaba2/index.html).
Results

Characteristics of study population

The baseline characteristics of controls and patients are listed in Table 1. The age of the controls ranged from 35 to 85 years with a mean age of 46.34±7.97, and the age of the breast cancer patients was within a range of 36–86 years, and their average age at diagnosis was 47.79±10.35 years respectively. According to the baseline characteristics, there was no significant difference in terms of epidemiological variables between cases and controls. However, a higher number of breast cancer patients (62.6% versus 57.0%) were from rural background compared to controls. More than 75% had regular menstrual cycles and about 176 (58.6%) patients were in premenopausal state and 124 (41.33%) in postmenopausal state. About 18.3% of breast cancer patients had smoking habit as presented in Table 1.

In the present study, clinicopathological profiles of breast cancer patients revealed that majority of the patients (66%) were at clinical stage T_0-T_2 (early stage) and with respect to information on steroid hormone receptor status, out of total patients, 176 (58.6%) patients

| Parameters                          | Breast cancer patients |
|------------------------------------|------------------------|
|                                    | Number | Percentage |
| Stage of the cancer                |         |            |
| T_0-T_2                            | 197     | 65.7       |
| T_3-T_4                            | 103     | 34.3       |
| ER^a status                        |         |            |
| Positive                           | 177     | 59.0       |
| Negative                           | 123     | 41.0       |
| PgR^b status                       |         |            |
| Positive                           | 168     | 56.0       |
| Negative                           | 132     | 44.0       |
| HER2/neu^c receptor status         |         |            |
| Positive                           | 163     | 54.33      |
| Negative                           | 111     | 37.0       |
| Missing Data                       | 26      | 8.6        |
| Triple Negative Receptor status    |         |            |
| Other combinations                 | 215     | 71.66      |
| Negative                           | 59      | 19.67      |
| Missing Data                       | 26      | 8.67       |
| Histological subtype               |         |            |
| Ductal Carcinoma                   | 247     | 82.33      |
| Lobular Carcinoma                  | 53      | 17.66      |
| Lymph nodal status                 |         |            |
| Positive                           | 220     | 73.33      |
| Negative                           | 80      | 26.66      |
| Metastasis                         |         |            |
| Absent                             | 198     | 66.0       |
| Present                            | 102     | 34.0       |

^aOestrogen receptor  
^bProgestrone receptor  
^cHuman epidermal growth factor receptor 2/neu receptor

Table 2. Clinicopathological parameters among the breast cancer patients.

https://doi.org/10.1371/journal.pone.0184448.t002
were ER positive, 167 (55.6%) were PgR positive and 163 (54.33%) Her2/nu positive whereas 59 (19.66%) were triple negative status. The histopathological classification of breast cancer at the time of diagnosis in our study showed that of all patients, 82.33% (247) had ductal carcinoma and 17.66% (53), had invasive lobular carcinoma. 73.33% of the patients had shown positive lymph node involvement at the time of diagnosis. Among the total cases, 102 (34%) reported metastasis as presented in Table 2. The SNPs of MMP1 (-1607 1G/2G), MMP3 (-1171 5A/6A) and MMP9 (-1562 C/T) were genotyped using specific primers and thermal cycling conditions as displayed in Table 3.

The distribution of genotype and allele frequencies of SNPs under study for 300 controls and 300 breast cancer patients is shown in Table 4 (S1 File).

### Table 3. Forward and reverse primers and PCR conditions for genotyping of selected polymorphic variants of MMP-1, -3 & -9 genes.

| SNP rsnumber | Assay | Primers | Ta | RE | Gel band pattern | Ref. |
|--------------|-------|---------|----|----|-----------------|------|
| -1607 1G/2G  | PCR-RFLP | 5'-gaccttttaacatagctctgtgctc-3' (f) 5'-ctttggagttgccataagcatag-3' (r) | 52˚C | Alu I | 1G- 241bp, 2G-28bp | [16] |
| -1171 5A/6A  | AS-PCR | 5A-ttgatgggggaaac (f) 5A-actcagagaaaaattaagg (r) 6A-ttgatgggggaaa (f) 6A-aaatattatatctacgcttt (r) | 54˚C | - | 5A- 226bp, 6A- 282bp | [19] |
| -1562 C/T    | AS-PCR | CF-5 aaaaaatttagccccgctttgggaac 3' CR-5'ctccccgagttcttagttatagtc 3' TF-5'aaatattagcccagctttggcgt 3' TR-5'gcctcccagtagctttatagtc 3' | 58˚C | - | C-296bp, T-220bp | [20] |

f-forward; r-reverse; Ta–Annealing temperature, RE- restriction Enzyme, AS-Allele Specific Ref-reference

https://doi.org/10.1371/journal.pone.0184448.t003

### Table 4. Genotype and allele frequencies distribution for MMP-1, MMP-3 and MMP-9 gene polymorphisms in controls and breast cancer subjects.

| MMP1–1607 1G>2G | Controls | BC Cases | OR (95%CI) | p-value |
|------------------|----------|----------|------------|---------|
| 1G1G             | 66 (22)  | 26 (8.6) | 1.0(ref)   | <0.01   |
| 1G2G             | 122 (40.7)| 108 (36) | 2.21(0.92–3.77) |    |
| 2G2G             | 112 (37.3)| 166(55.3)| 4.13(2.14–7.00) | <0.01   |
| 1G               | 254(0.42)| 160(0.27) |          |         |
| 2G               | 346(0.58)| 440(0.73) | 2.01(1.57–2.59) | <0.0001 |

**MMP3–1171 5A>6A**

| 5A5A            | 88 (29.3)| 59 (19.7) |          |         |
| 5A6A            | 171 (57) | 189 (63)  | 1.65 (1.12–2.43) | 0.011   |
| 6A6A            | 41 (13.7)| 52 (17.3) | 1.89 (1.12–3.2) | 0.023   |
| 5A              | 347 (0.58)| 347 (0.58) |          |         |
| 6A              | 253 (0.42)| 253 (0.42) | 1.3 (1.04–1.64) | 0.02    |

**MMP9–1562 C>T**

| CC | 150 (50) | 121 (40.3) |          |         |
| CT | 101 (33.7) | 107 (35.7) | 1.31 (0.91–1.88) | 0.07    |
| TT | 49 (16.3) | 72 (24) | 1.82 (1.18–2.81) | 0.02    |
| C  | 401 (0.67) | 349 (0.58) |          |         |
| T  | 199 (0.33) | 251 (0.42) | 1.44 (1.14–1.83) | 0.0001  |

*p<0.05 is considered to be statistically significant

https://doi.org/10.1371/journal.pone.0184448.t004

---

---
Distribution of allelic and genotype frequencies of 1G -1607 2G polymorphism in MMP1 gene

The distribution of allelic frequencies of MMP1–1607 1G and 2G alleles were found to be 0.42 and 0.58 in controls, compared with 0.27 and 0.73 in patients respectively, thus an increased frequency of 2G-allele of MMP1 (OR 2.01, 95%CI 1.57–2.59, \(p<0.001\)) was observed in BC subjects (\(p<0.01\)) as summarized in Table 4. The genotype distribution in controls were 22% (1G/1G), 40.7% (1G/2G), and 37.3% (2G/2G), while in patients were 8.7% (1G/1G), 36.0% (1G/2G) and 55.3% (2G/2G), respectively. The frequency distribution in patients had shown slight deviation from those expected from the Hardy Weinberg equilibrium (\(p = 0.18\) and 0.04 for controls and cases respectively). The frequency of variant homozygote (2G/2G) was found to be significantly high in the BC group compared to controls with 4 folds increased risk for BC (OR 95% CI 4.13, 2.14–7.00, \(p<0.0001\)).

Distribution of allelic and genotype frequencies of 5A -1171 6A polymorphism in MMP3 gene

The distribution of allelic frequencies of MMP3–1171 5A and 6A alleles were found to be 0.58 and 0.42 in controls, compared with 0.51 and 0.49 in patients respectively, showing an increased frequency of 6A-allele of MMP3 (OR 1.30, 95% CI 1.04–1.64, \(p<0.023\)) as summarized in Table 4. The frequencies of the three MMP3 genotypes in controls were 29.3% (5A/5A), 57.0% (5A/6A) and 13.7% (6A/6A) while, in BC patients the frequencies were 19.7% (5A/5A), 63% (5A/6A) and 17.3% (6A/6A) and there was a deviation from those expected from the Hardy Weinberg equilibrium (\(p = 0.004\), \(p = 0.0001\), for controls and cases respectively). The frequency of homozygote variant (6A/6A) and heterozygote 5A/6A were found to be significantly high in the BC group compared to controls with 1.89 and 1.65 fold increased risk for BC (OR 95% CI 1.89 1.12–3.20, \(p = 0.01\), OR 95% CI 1.65, 1.12–2.43 \(p = 0.01\)).

Distribution of allelic and genotype frequencies of C-1562 T polymorphisms in MMP9 gene

The distribution of allelic frequencies of MMP9–1562 C and T alleles were found to be 0.67 and 0.33 in controls, compared with 0.58 and 0.42 in patients respectively, with an increased frequency of T-allele of MMP9 (OR 1.44, 95% CI 1.14–1.83, \(p<0.0023\)) was observed in BC patients as summarized in Table 4. The frequencies of the three MMP9 genotypes in controls were 50% (C/C), 33.7% (C/T) and 16.3% (T/T) while, in BC patients were 40.3% (C/C), 35.7% (C/T) and 24% (T/T), deviated from those expected from the Hardy Weinberg equilibrium (\(p<0.01\)). The frequency of variant homozygote (T/T) was found to be higher in the BC group compared to controls with 1.82 fold increased risk for BC (OR 95% CI 1.82 1.18–2.81, \(p = 0.02\)).

Stratified analysis of MMP1–1607 1G/2G, MMP3–1171 5A/6A and MMP9–1562 C/T gene polymorphisms in association with clinicopathological features

Genotype distribution of MMP1–1607 1G/2G polymorphism with respect to clinical characteristics is summarized in Table 5. It has been observed that the frequency of individuals with 1G allele was high with HER2/neu receptor negative status indicating protection against the disease. The other variables like stage of cancer, histological type of tumor, ER/PR status,
lymph node status and metastasis status have not revealed any significant association with MMP-1–1607 1G/2G polymorphism.

However, 5A/6A genotype of MMP3–1171 5A/6A polymorphism was found to be significantly associated with lymph node positive cases (OR 2.58, 95%CI 1.39–4.8, p = 0.01). There was no significant association of MMP9–1562 C/T gene polymorphism with respect to clinico-pathological variables as summarized in Table 5 (S1 File).

**Haplotype analysis**

Haplotype analysis of MMP1 and MMP3 genes present on chromosome 11q was performed to calculate the combined effect of MMP1–1607 1G/2G and MMP3–1171 5A/6A polymorphisms

### Table 5. Association of the MMP1–1607 1G>2G, MMP3–1171 5A>6A and MMP9–1562 C>T genotypes with breast cancer susceptibility and clinico-pathological characteristics.

| Characteristics | MMP1–1607 1G>2G | MMP3–1171 5A>6A | MMP9–1562 C>T |
|-----------------|-----------------|-----------------|---------------|
| **Stage of the cancer** | | | |
| Early | 1G1G 17 (8.6) 75 (38.1) 105 (53.3) | 2G2G 66 (33.5) 83 (42.1) 48 (24.4) | 6A6A 79 (40.1) 69 (35.0) 49 (24.9) |
| Late | 1G1G 9 (8.7) 33 (32) | 2G2G 61 (59.2) 43 (41.8) 37 (35.9) | 6A6A 23 (22.3) 42 (40.8) 38 (36.9) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.61 | 0.37 | 0.33 |
| **Type of the cancer** | | | |
| Ductal | 1G1G 21 (8.5) 96 (38.9) 130 (52.6) | 2G2G 47 (19.0) 158 (64.0) 42 (17.0) | 6A6A 96 (38.9) 89 (36.0) 62 (25.1) |
| Lobular | 1G1G 5 (9.4) 12 (22.6) 36 (67.9) | 2G2G 12 (22.6) 31 (58.5) 10 (18.9) | 6A6A 25 (47.2) 18 (34.0) 10 (18.9) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.14 | 0.74 | 0.45 |
| **Axillary Lymph node Status** | | | |
| Positive | 1G1G 19 (8.6) 77 (35) 124 (56.4) | 2G2G 147 (66.8) 39 (17.7) 88 (40.0) | 6A6A 79 (35.9) 53 (24.1) |
| Negative | 1G1G 7 (8.8) 31 (38.8) 42 (52.5) | 2G2G 25 (31.2) 42 (52.5) 13 (6.2) | 6A6A 33 (41.2) 28 (35.0) 19 (23.8) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.82 | 0.86 | 0.01* |
| **ER Status** | | | |
| Positive | 1G1G 16 (9.0) 66 (37.3) 95 (53.7) | 2G2G 110 (62.1) 32 (18.1) 73 (41.2) | 6A6A 62 (35.0) 42 (23.7) |
| Negative | 1G1G 10 (8.1) 42 (34.1) 71 (57.7) | 2G2G 24 (19.5) 79 (64.2) 20 (16.3) | 6A6A 48 (39.0) 45 (36.6) 30 (24.4) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.08 | 0.85 | 0.89 |
| **PgR Status** | | | |
| Positive | 1G1G 16 (9.6) 62 (37.1) 89 (53.3) | 2G2G 102 (60.7) 32 (19.1) 16 (9.6) | 6A6A 62 (37.1) 89 (53.3) |
| Negative | 1G1G 10 (7.5) 46 (34.6) 77 (57.7) | 2G2G 78 (65.9) 20 (19.1) 10 (7.5) | 6A6A 46 (34.6) 77 (57.9) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.77 | 0.45 | 0.92 |
| **HER2/neu Status** | | | |
| Positive | 1G1G 11 (6.8) 45 (24.6) 107 (56.6) | 2G2G 34 (20.2) 102 (60.7) 32 (19.1) | 6A6A 16 (9.6) 62 (37.1) 89 (53.3) |
| Negative | 1G1G 12 (10.8) 49 (44.1) 50 (45) | 2G2G 17 (15.3) 73 (65.8) 21 (18.9) | 6A6A 47 (42.3) 42 (37.8) 22 (18.8) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.003 | 0.003 | 0.003 |
| **Distant Metastasis Status** | | | |
| Positive | 1G1G 10 (9.8) 36 (35.3) 56 (54.9) | 2G2G 19 (18.6) 64 (62.8) 19 (18.6) | 6A6A 37 (36.3) 38 (37.2) 27 (26.5) |
| Negative | 1G1G 16 (8.1) 72 (36.4) 110 (55.6) | 2G2G 40 (20.2) 125 (63.1) 33 (16.7) | 6A6A 84 (42.4) 69 (34.9) 45 (22.7) |
| **OR (95% CI)** | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| p-value | 0.87 | 0.87 | 0.87 |

*p<0.05 is considered to be statistically significant*
on breast cancer. Out of the four haplotypes obtained, the 2G (MMP1)-5A (MMP3) was the most commonly found haplotype therefore was considered as reference. The haplotype 1G-5A (alleles in order of MMP-1 & MMP-3) frequency was high in controls than in patients and might confer protection against breast cancer (OR 0.45, 95% CI 0.29–0.69, p < 0.0001) Table 6 (S1 File).

**Linkage disequilibrium**

In the present study, pairwise LD estimate was obtained for the MMP1, MMP3 and MMP9 gene polymorphisms in cases and control group separately. The analysis revealed that most of the SNP marker combinations exhibited perfect LD scores, with the exception of few combinations that showed differential pattern of high LD scores in each of the analysis group (controls and cases). The SNP loci combination of MMP3-MMP1 and MMP9-MMP1 showed a perfect LD in controls and cases, however $D^\prime = 0.92$ and $D^\prime = 0.61$ was observed between MMP3-MMP9 in controls and cases respectively as shown in Table 7 and Fig 1 (S1 File).

**Multifactor dimensionality reduction (MDR) Analysis**

Association of higher order interactions with breast cancer risk was analyzed by MDR analysis as summarized in Fig 2. The interaction information analysis revealed moderate effect between the markers -1607 1G/2G of MMP1, -1171 5A/6A of MMP3 and -1562 C/T of MMP9 genes which were conferring risk towards the progression of the breast cancer. High-risk and low-risk genotypic combinations were determined based on the threshold value, which was 1

| Variable | Controls | Cases | Total Frequency | OR (95% CI) | p-Value |
|----------|----------|-------|----------------|-------------|---------|
| MMP1-1607 1G/2G MMP3-1171 5A/6A | | | | | |
| 2G 5A | 0.3535 | 0.3836 | 0.3535 | 1.00 | 19 |
| 2G 6A | 0.3015 | 0.3497 | 0.655 | 1.28(0.89–1.83) | |
| 1G 5A | 0.1915 | 0.1281 | 0.8465 | 0.45(0.29–0.69) | <0.0001* |
| 1G 6A | 0.1535 | 0.1386 | 1.0 | 0.74(0.49–1.11) | 0.14 |

**Global haplotype association p-value: <0.0001**

*p<0.05 is considered to be statistically significant

https://doi.org/10.1371/journal.pone.0184448.1006

*1Lod score LOD was defined as log10 (L1/L0), where L1 = likelihood of the data under linkage disequilibrium, and L0 = likelihood of the data under linkage equilibrium. $D^\prime$ was calculated as follows: $D^\prime = D^\prime$ (normalized linkage disequilibrium measure) divided by the theoretical maximum for the observed allele frequencies.

https://doi.org/10.1371/journal.pone.0184448.t007
(300/300) for the present data where the TT genotype of MMP9, 6A6A genotype of MMP3 and 2G2G genotype of MMP1 conferred a 3 fold high risk (8/2) for breast cancer as shown in Table 8 (S1 File).

Dendrogram interaction analysis of our data showed that MMP1–1607 1G/2G and MMP9 –1562 C/T gene exhibited a strong redundant effect or correlation with the disease phenotype while MMP3–1171 5A/6A had an additive effect on the risk of breast cancer development as shown in Fig 3.

Survival analysis

The median survival rate was decreased in risk genotypes among all the selected SNPs of -1607 2G2G (48.0), -1171 6A6A (45.0) and -1562 TT (42.0) compared to protective genotypes of -1607 1G1G (50.0), -1171 5A5A (34.0) and -1562 CC (40.0) as summarized in Table 9. However, the genotypes did not significantly affect survival time among breast cancer patients (p>0.05) (Fig 4) (S2 File).

With respect to clinicopathological characteristics, our analysis revealed a significant association between median 5 year survival rate with late stage of breast cancer at diagnosis, negative HER2/neu receptor status and presence of metastasis (p<0.05).

In addition, the multivariate cox regression analysis also confirmed the results indicating the significant influence of the clinicopathological variables on breast cancer development and progression Table 10 (S2 File).
In silico analysis

The prediction of transcription factors binding sites (TFBSs) for MMP-1–1607 1G>2G polymorphism has shown that 1G allele has no TFBS whereas 2G allele has a binding site for C/EBP alpha (CCAAT/enhancer-binding protein alpha) site as depicted in Fig 5. With respect to MMP3–1171 5A>6A polymorphism, our analysis revealed that 5A-allele has Nf-kappaB TFBS while 6A allele results in loss of Nf-kappaB binding site as depicted in Fig 5. Similarly, for MMP9–1562 C>T polymorphism, C-allele has a Sp1 TFBS, whereas T-allele results in the loss of Sp1 TFBS as shown in the Fig 5.

Table 8. Summary of gene-gene interaction by MDR analysis.

| Locus & Combinations | Genes       | Training Balance Accuracy | Testing Error Balance Accuracy | p-value (sign test) | CVC Consistency |
|----------------------|-------------|----------------------------|--------------------------------|---------------------|----------------|
| One loci             | MMP1        | 0.59                       | 0.41                           | 8(0.054)            | 10/10          |
| Two loci             | MMP1, MMP9  | 0.61                       | 0.39                           | 8(0.054)            | 10/10          |
| Three loci           | MMP1, MMP3 and MMP9 | 0.61 | 0.39 | 7(0.171) | 10/10 |
Discussion

Carcinogenesis is a growing health problem worldwide that is characterized at cellular level by self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, angiogenesis, tissue invasion, and metastasis. [24]. MMPs are proteolytic enzymes that degrade extracellular matrix and basement membrane. Most of the studied SNPs have been reported to have functional [25–27] a role in breast cancer progression. MMP-1 (interstitial collagenase) and MMP-3 (stromelysin) are multifunctional enzymes and structurally related genes localized to chromosome 11q, involved in physiological and pathological tissue remodeling [28]. MMP3 is known to lyse basal membrane collagen and induce the synthesis of other MMPs such as MMP1 and MMP9 (Gelatinase B) [29]. MMP9 a key player in angiogenesis, is present on chromosome 20q. The present study

Table 9. Kaplan-Meier survival curve for 5-years survival rate in months of MMP1 (-1607 1G/2G), MMP3 (-1171 5A/6A) and MMP9 (-1562 C/T) polymorphisms.

| Genotype | N (%) | Event (Death) | (5 years survival in months) Mean±SEM | Median | χ² p-valueα |
|----------|-------|---------------|--------------------------------------|--------|-------------|
| MMP1 (-1607 1G/2G) Gene Polymorphism | | | | | |
| 1G1G     | 22(8.94) | 6(7.60) | 55.590±3.35 | 50.00 | 0.51 |
| 1G2G     | 94(38.21) | 35(44.30) | 51.367±1.60 | 41.00 |
| 2G2G     | 130(52.84) | 38(48.10) | 54.469±1.27 | 48.00 |
| Total    | 246 | 79 | 53.266±0.95 | 42.00 |
| MMP3 (-1171 5A/6A) Gene Polymorphism | | | | | |
| 5A5A     | 46(18.67) | 10(12.65) | 54.924±2.22 | 34.00 | 0.09 |
| 5A6A     | 153(62.19) | 49(62.02) | 53.265±1.12 | 42.00 |
| 6A6A     | 47(19.13) | 20(25.33) | 51.508±2.35 | 45.00 |
| Total    | 246 | 79 | 53.266±0.9 | 53.00 |
| MMP9 (-1562 C/T) Gene Polymorphism | | | | | |
| CC       | 96(39.02) | 27(34.18) | 53.630±1.56 | 40.00 | 0.495 |
| CT       | 89(36.17) | 33(41.80) | 53.133±1.40 | 46.00 |
| TT       | 61(24.80) | 19(24.01) | 52.914±2.14 | 42.00 |
| Total    | 246 | 79 | 53.266±0.94 | 42.00 |

αLog Rank p-values by mantle COX regression statistically significant at p<0.05

https://doi.org/10.1371/journal.pone.0184448.t009
mainly focused on the analysis of synergistic effects of three functional SNPs of MMP1 (rs1799750) -1607 1G/2G, MMP3 (rs35068180) -1171 5A/6A and MMP9 (rs3918242) -1562 C/T genes in relation to breast cancer development and progression.

The promoter genetic variation of MMP-1 gene arises from insertion or deletion of a guanine nucleotide (G) at position -1607 relative to the transcriptional start site; consequently, one allele (insertion) has two Gs (2G), whereas the other allele (deletion) has only one G at this position (1G). The insertion creates the core sequence (5′-GGA-3′) of a binding site for the Ets transcription factors, and it was demonstrated in vitro that the 2G allele had a higher transcriptional activity [30]. In the present study as summarized in Table 4, the frequency of 2G-allele was found to be predominant in breast cancer group compared to controls, with 2 folds increased risk for BC our results are in absolute conformity with published earlier data in colorectal carcinoma and renal cell carcinoma [31]. Further 2G-allele was also found to be associated with invasiveness of lung cancer and endometrial cancer [32].

In contrast the insertion of an adenosine in the -1171 position in the MMP-3 gene promoter sequence halves its transcriptional activity [33]. It is known that the higher transcriptional activity associated with the 5A allele may enhance tumor invasiveness [34]. Our study revealed that an individual with 5A/6A genotype has an increased risk for the development of breast cancer (p = 0.01).

Our findings are in accordance with earlier studies carried out on non-small cell lung carcinoma in north china population [35] and early stage oral sub-mucous fibrosis, head and neck carcinoma [36]. Further, our findings are in agreement with meta-analysis report on matrix metalloproteinase 1& 3 and cancer risk [37].

MMP9 promoter region with a C to T substitution at position -1562 in MMP-9 promoter region may result in a loss of binding of a nuclear protein with increase in transcriptional activity [38]. With respect to MMP9–1562 C/T promoter polymorphism, our study revealed that the frequency of T-allele was found to be predominant in breast cancer group compared to controls, with a 1.44 folds increased risk for BC. These reports were in accordance with that of multiple cancers like lung [39] and colorectal cancer [40]. Further, Przybylowska et al (2006) has shown that the T-allele of MMP9–1562 C/T was associated with the tumor expression and influences the malignant potential of breast carcinoma susceptibility [38].

Fig 4. Kaplan-Meier 5 years survival analysis curves with respect to MMP1-16071G/2G, MMP3-1171 5A/6A and MMP9–1562 C/T polymorphisms in breast cancer patients.

https://doi.org/10.1371/journal.pone.0184448.g004
Overexpression of MMP1, MMP3 and MMP9 genes have been found to be positively associated with the clinicopathological characteristics of several malignancies [41–44]. In the present study SNPs of MMP1, MMP3 and MMP9 genes were correlated with clinicopathological features for their association in breast cancer progression and susceptibility. Our results revealed a significant association of 2G/2G genotype of MMP1-1607 with steroid hormonal receptor status and metastasis, suggesting the importance of 2G/2G genotype in the progression of breast cancer. The MMP3-1171 5A/6A polymorphism, 5A/6A genotype was significantly associated with positive lymph node involvement.

The LD analysis was carried for both controls and BC patients independently to determine the risk conferring genetic markers. The SNP loci combination was in perfect LD (D' = 1), demonstrating their strong association. Haplotype analysis of the MMP gene cluster on Table 10. Kaplan-Meier survival and cox regression analysis of clinicopathological characteristics on 5-years survival rate of breast cancer patients.

| Characteristics                  | N (%)  | Event (Death) | (5 years in months) Mean±SEM | Median | p-value | HRa | 95% CIb | p-value |
|----------------------------------|--------|---------------|------------------------------|--------|---------|-----|---------|---------|
| Stage of the cancer              |        |               |                              |        |         |     |         |         |
| Early Stage                      | 163 (66.26) | 41 (25.15) | 134.30±8.07                  | 59.0   | 0.002*  | 1(Ref)| 1.962  | 1.26–3.05 |
| Late stage                       | 83 (33.37)  | 38 (45.78) | 79.61±7.32                   | 48.0   |          |     |         |         |
| Size of Tumor                    |        |               |                              |        |         |     |         |         |
| <50mm                            | 178 (72.35) | 52 (29.21) | 122.69±8.31                  | 57.0   | 0.05*   | 1(Ref)| 0.63   | 0.39–1.07 |
| >50mm                            | 68 (27.64)  | 27 (39.70) | 74.47±5.54                   | 47.0   |          |     |         |         |
| Type of Cancer                   |        |               |                              |        |         |     |         |         |
| Ductal                           | 205 (83.34) | 67 (32.69) | 113.56±8.81                  | 59.0   | 0.28    | 1(Ref)| 0.715  | 0.38–1.32 |
| Lobular                          | 41 (16.66)  | 12 (29.27) | 116.05±13.14                 | 40.0   |          |     |         |         |
| Lymph node status                |        |               |                              |        |         |     |         |         |
| Lymph node -Ve                   | 61 (24.79)  | 17 (27.89) | 133.70±11.80                 | 47.0   | 0.69    | 1(Ref)|         | 0.69    |
| Lymph node +Ve                   | 185 (75.21) | 62 (33.51) | 105.40±7.54                  | 57.0   | 1.113   | 0.65–1.90 |         |         |
| ER Status                        |        |               |                              |        |         |     |         |         |
| ER positive                      | 147 (59.75) | 49 (33.34) | 117.08±8.41                  | 59.0   | 0.76    | 1(Ref)| 1.08   | 0.68–1.72 |
| ER negative                      | 99 (40.24)  | 30 (30.30) | 82.06±4.91                   | 57.0   |          |     |         |         |
| PgR Status                       |        |               |                              |        |         |     |         |         |
| PgR positive                     | 141 (57.31) | 50 (35.47) | 113.06±8.43                  | 43.0   | 0.47    | 1(Ref)| 0.84   | 0.533–1.33 |
| PgR negative                     | 105 (42.68) | 29 (27.62) | 94.74±5.42                   | 59.0   |          |     |         |         |
| HER2/neu receptor status         |        |               |                              |        |         |     |         |         |
| HER2/neu-ve                      | 130 (52.84) | 32 (24.62) | 128.03±9.87                  | 58.0   | 0.002*  | 1(Ref)| 2.16   | 1.34–3.46 |
| HER2/neu-ve                      | 91 (36.99)  | 40 (43.96) | 73.06±5.03                   | 57.0   |          |     |         |         |
| NA                               | 25 (10.16)  | 7 (28.0) | 100.75±8.85                  | 56.0   |          |     |         |         |
| Triple Receptor status (ER, PgR and HER2/neu) | | | | | | | | |
| Other combinations               | 175 (71.13) | 55 (31.43) | 117.00±8.45                  | 59.0   | 0.47    | 1(Ref)| 1.22   | 1.33–3.23 |
| Negative                         | 46 (18.69)  | 17 (36.96) | 100.75±8.85                  | 57.0   |          |     |         |         |
| NA                               | 25 (10.16)  | 7 (28.0)  | 114.55±7.24                  | 56.0   |          |     |         |         |
| Metastasis                       |        |               |                              |        |         |     |         |         |
| No metastasis                    | 162 (65.85) | 38 (23.46) | 136.88±8.15                  | 56.0   | 0.001*  | 1(Ref)| 2.07   | 1.26–3.05 |
| Metastasis yes                   | 84 (34.14)  | 41 (48.90) | 76.28±7.18                   | 57.0   |          |     |         |         |

5 years OS in months; Log Rank p-values by mantle COX regression. p value <0.05 Significant

aHR: Hazards ratio,
b95% Class interval,
*p value <0.05 Significant

https://doi.org/10.1371/journal.pone.0184448.t010
chromosome 11q has shown a significant association with 1G-5A variant alleles of MMP1 and MMP3 gene polymorphisms.

Further, the MDR analysis was carried out to study gene–gene interactions, the result of the present study suggests that the 2G-allele of MMP1-1607 1G/2G, and T-allele of MMP9-1562 C/T may be associated with altered enzyme activity, favours tumour-related mechanisms, and promotes tumor development and progression.

The interaction dendrogram also further confirmed that MMP-1607 1G/2G and MMP3–1171 5A/6A SNPs have strong correlation whereas, MMP9-1562 C/T polymorphism has an additive effect on the risk of breast cancer development.

Furthermore, the SNPs in promoter region of MMP-1, -3 and -9 genes might be involved in gain or loss of potential transcription factor binding sites (TFBSs), therefore we analysed the TFBSs for the SNPs under study using AliBaba2.1 online tool. Our results revealed that for MMP1–1607 1G>2G polymorphism, the 2G allele was associated with transcription factor binding sites for C/EBPalpha (also known as CCAAT/enhancer-binding protein alpha), leading to enhanced activity of the gene. Similarly, regarding MMP3–1171 5A>6A polymorphism, 5A allele was associated with Nf-KappaB site, while 6A allele was associated with lack of Nf-kappaB site, leading to reduced transcription activity. Likewise, pertaining to MMP9–1562 C>T polymorphism, C allele was associated with Sp1 nuclear protein while, T allele was associated with lack of Sp1 site, leading to increased activity of the gene.

In addition, the associations of MMP1, 3 and 9 SNPs with 5- years survival rate were assessed using Kaplan-Meier analysis. Our data showed a decreased survival rate for risk genotypes of all selected SNPs of MMP-1, -3 & -9 genes but statistically insignificant at p<0.05. However, a significant association of the clinicopathological characteristics such as late stage at diagnosis, HER2/neu receptor negative status and presence of metastasis with 5- years survival rate was observed (p<0.05), suggesting the importance of these clinicopathological features in the progression of breast cancer.

Overall, our results revealed that the polymorphisms in the promoter region of MMP1, MMP3 and MMP9 when correlated with clinicopathological characteristics and survival rate have shown significant effects on the risk and progression of breast cancer, substantiated by in-silico analysis. These functional polymorphisms in MMPs could lead to altered gene expression, subsequently creating imbalance in the vital MMP system that results in excessive ECM degradation and deregulated ECM dynamics in cancer development.

In conclusion, our results suggest that MMP1–1607 1G/2G, MMP3–1171 5A/6A and MMP9–1562 C/T gene polymorphisms have strong correlation with breast cancer. The 2G–6A
haplotype (minor alleles of MMP-1 and MMP-3 respectively) has shown an increased susceptibility to BC, may display potential application as biological marker for identification of individuals at risk. The interactions of MMPs with breast cancer related environmental and clinical risk factors such as lymph node involvement have a strong correlation and influence the survival rate, suggesting their potential role in the breast carcinogenesis.

To the best of our knowledge this is the first study reporting on the synergistic effects of SNPs in MMP1, MMP3, and MMP9 genes in correlation with epidemiological and clinical variables also with LD, MDR, survival rate and In-silico analysis. However, our study has several limitations. Firstly, a small study that was analysed in South Indian population, because we restricted the study subjects to individuals of South Indian ethnicity; it is uncertain whether these results can be generalized to other populations. Second, there were few patients with missing hormonal receptor status, which may bias the results indicating an association with advanced disease status. Third, our LD and MDR analysis included only 600 samples and this may have limited the power of the pooled results. Therefore, collaborative studies on different populations are necessary to corroborate our findings.

Supporting information

S1 File. Supporting information database file (6 excel sheets titled- Control data, BC data, MDR data, LD controls, LD BC cases and SNP info).
(XLS)

S2 File. Supporting information database file (1 excel sheet titled- Kaplan-Meier survival data).
(XLSX)

Acknowledgments

We thankfully acknowledge the subjects for their participation in this study. We thank UGC-RGNF No.F.16-1784(SC)/2010(SA-III) for fellowship and UGC-MRP (UGC MRP-F.No.42-52/2013[SR]) & DST-PURSE New Delhi, INDIA, for providing consumables.

Author Contributions

Conceptualization: Chiranjeevi Padala, Mohini Aiyengar Tupurani, Surekha Rani Hanumanth.

Data curation: Chiranjeevi Padala, Mohini Aiyengar Tupurani, Nivas Shyamala, Mrudula Spurthi Kondapalli, Kishore kumar Gundapaneni.

Formal analysis: Chiranjeevi Padala, Mohini Aiyengar Tupurani, Surekha Rani Hanumanth.

Investigation: Chiranjeevi Padala, Mohini Aiyengar Tupurani.

Methodology: Chiranjeevi Padala, Mohini Aiyengar Tupurani, Kaushik Puranam, Srilatha Gantala, Mrudula Spurthi Kondapalli, Saraswati Mudigonda, Rajesh Kumar Galimudi, Keerthi Kupsal, Santoshi Rani Nanchari.

Resources: Kaushik Puranam, Kishore kumar Gundapaneni, Rajesh Kumar Galimudi, Santoshi Rani Nanchari, Uday Chavan, Sanjeeva kumari Chinta, Srinivasulu Mukta, Vishnupriya Satti.

Supervision: Surekha Rani Hanumanth.

Validation: Mohini Aiyengar Tupurani.
Visualization: Mohini Aiyengar Tupurani.

Writing – original draft: Chiranjeevi Padala, Mohini Aiyengar Tupurani.

Writing – review & editing: Chiranjeevi Padala, Mohini Aiyengar Tupurani, Kaushik Puranam, Sanjeeva Kumari Chinta, Vishnupriya Satti, Surekha Rani Hanumanth.

References

1. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373:2005–2014. https://doi.org/10.1056/NEJMoa1510764 PMID: 26412349

2. Mailer O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia. 2010; 15:301–318. https://doi.org/10.1007/s10911-010-9188-6 PMID: 20811805

3. Decock J, Pariadens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet. 2008; 73:197–211. https://doi.org/10.1111/j.1399-0004.2007.00946.x PMID: 18177467

4. Gonzalez-Villaseña V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodríguez-Aguayo C, Fernandez-De Thomas RJ, et al. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clin Cancer Res. 2016; 21:2127–2137. https://doi.org/10.1158/1078-0432.CCR-15-2278 PMID: 25958279

5. Egeland M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2:161–174. https://doi.org/10.1038/nrc745 PMID: 11990853

6. Che Y-L, Luo S-J, Li G, Cheng M, Gao Y-M, Li X-M, et al. The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis. Cancer Lett. 2015; 359:241–249. https://doi.org/10.1016/j.canlet.2015.01.019 PMID: 25617801

7. Bäck M, Ketelhut DFJ, Agewall S. Matrix Metalloproteinases in Atherothrombosis. Prog Cardiovasc Dis. 2010; 52:410–428. https://doi.org/10.1016/j.pcad.2009.12.002 PMID: 20226959

8. Johansson N, Saarialho-Kere U, Airola K, Herva R, Niissinen L, Westermarck J, et al. Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, pericellular cells, and osteoblasts during human fetal bone development. Dev Dyn. 1997; 208:387–397. https://doi.org/10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA93.0.CO;2-E PMID: 9066642

9. Liu L, Wu J, Wu C, Wang Y, Zhong R, Zhang X, et al. A functional polymorphism (-1607 1G→2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer. 2011; 117:5172–5181. https://doi.org/10.1002/cncr.26154 PMID: 21523769

10. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25:9–34. https://doi.org/10.1007/s10555-006-7886-9 PMID: 16680569

11. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 2001; 276:7549–7558. J Biol Chem. https://doi.org/10.1074/jbc.M010242200 PMID: 1114309

12. Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res. 2007; 13:6673–6680. https://doi.org/10.1158/1078-0432.CCR-07-0177 PMID: 18006768

13. Ghilaridi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnelli E, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002; 8:3820–3823. PMID: 12473595.

14. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res. 2004; 23:121–125. PMID: 15149160

15. Kripp P, Langsenlehner U, Renner W, Yazdani-Biuki B, Köppel H, Leithner A, et al. The SA/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res. 2004; 10:3518–3520. https://doi.org/10.1158/1078-0432.CCR-04-0010 PMID: 15161710

16. Zhu Y, Spiltz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001; 61(21):7825–7829. PMID: 11691799.

17. Sinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care (Basel). 2013; 8(2):149–154. https://doi.org/10.1159/000350774 PMID: 24415964
18. Chiranjeevi P, Sputhi KM, Rani NS, Kumar GR, Aliygar TM, Saraswat M, et al. Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer. Tumor Biol. 2014; 35:1351–1356. https://doi.org/10.1007/s13277-013-1181-5 PMID: 24357512

19. Morosova EB, Chukhlovin AB, Kulagina NV, Kipich NV, Totolian AA. Functional gene polymorphism of matrix metalloproteinase-1 is associated with benign hyperplasia of myo- and endometrium in the Russian population. Genet Test Mol Biomarkers. 2012; 16(9): 1032–7. https://doi.org/10.1089/gtmb.2011.0376 PMID: 22853432

20. Žívković M, Raković A, Stanković A. Allele-specific detection of C-1562T polymorphism in the matrix metalloproteinase-9 gene: Genotyping by MADGE. J Neuroimmunol. 2006; 39:630–632.

21. Solé X, Guiné E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22:1928–1929. https://doi.org/10.1093/bioinformatics/bti268 PMID: 16720584

22. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;23; 105(5):709–22. https://doi.org/10.1038/bjc.2011.254 PMID: 21772329

23. Kishore Kumar G, Rajesh Kumar G, Mrudula Sputhi K, Nivas S, Chiranjeevi P, Ali A, et al. Polymorphisms of extrinsic death receptor apoptotic genes (FAS-670 G>A, FASL-844 T>C) in coronary artery disease. Apoptosis.2016; 21:558–565. https://doi.org/10.1007/s10495-016-1232-7 PMID: 26922070

24. Bayram S, Ulger Y, Sümübl AT, Kaya BY, Rencüzoğulları A, Genç A, Sevgiler Y, Bozkurt O, Rencüzoğulları E, et al. A functional HOTAIR rs920778 polymorphism does not contribute to gastric cancer in a Turkish population: a case-control study. Fam Cancer. 2015; 14:561–567. https://doi.org/10.1007/s10549-015-9813-0 PMID: 25980897

25. Ding C, Chen X, Zhang P, Huang J, Xu Y, Chen N, et al. Matrix Metalloproteinase-3–1171 5A/6A Polymorphism with cancer risk: A meta-analysis of 41 studies. PLoS One. 2014; 9(1): e87562. https://doi.org/10.1371/journal.pone.0087562 PMID: 24489939

26. Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 promoter and its inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat. 2007; 103:61–69. https://doi.org/10.1007/10549-006-9345-2 PMID: 17033924

27. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial Collagenases as Markers of Tumor Progression. Clin Cancer Res. 2000; 6:4823–4830. PMID: 11156241

28. Rutter JL, Mitchell TI, Butticé G, Butticé G, Meyers J, Gusella JF, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998;53: 5321–5325. PMID: 9850057.

29. Hirata H, Naito K, Yoshihiro S, Matsuya H, Suehiro Y, Hinoda Y. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer. 2003; 106:372–374. https://doi.org/10.1002/ijc.11229 PMID: 12845675

30. Nishioya Y, Sagae S, Nishikawa A, Ishioka S, Kudo R. A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett. 2003; 201:49–55. PMID: 14550952.

31. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996; 271:13065–13066. PMID: 8662992.

32. Yang X, Hu JW, Qiu MT, Li M, Yin R, Wang J, et al. Association of matrix metalloproteinase-3–1171 (5A>6A) polymorphism with cancer risk: A meta-analysis of 41 studies. PLoS One. 2014; 9(1): e87562. https://doi.org/10.1371/journal.pone.0087562 PMID: 24489939

33. Chaudhary AK, Singh M, Bhati AC, Singh M, Shukla S, Singh AK, et al. Synergistic effect of stromelysin-1 (matrix polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer. 2010; 10: 360–369.
37. Peng B, Cao L, Wang W, Xian L, Jiang D, Zhao J, et al. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: A meta-analysis of 50 case-control studies. Mutagenesis. 2010; 25:41–48. https://doi.org/10.1093/mutage/gep041 PMID: 19843588

38. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006; 95:65–72. https://doi.org/10.1007/s10549-005-9042-6 PMID: 16267613

39. Li H, Liang X, Qin X, Cai S, Yu S. Association of matrix metalloproteinase family gene polymorphisms with lung cancer risk: logistic regression and generalized odds of published data. Sci Rep. 2015; 5:10056. https://doi.org/10.1038/srep10056 PMID: 26198673

40. Woo M, Park K, Nam J, Kim JC. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2007; 22:1064–1070. https://doi.org/10.1111/j.1440-1746.2006.04424.x PMID: 17608852

41. Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996; 2:461–462. https://doi.org/10.1038/nm0496-461 PMID: 8597958

42. Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S. Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis. 2004; 19:518–524. https://doi.org/10.1007/s00384-004-0592-6 PMID: 15103490

43. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002; 41:289–296. https://doi.org/10.1080/02841860260088485 PMID: 12195749

44. Wieczorek E, Reszka E, Jablonowski Z, Jablonska E, Beata Krol M, Grzegorczyk A, et al. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), and bladder cancer susceptibility. BJU Int. 2013; 112: 1207–1214. https://doi.org/10.1111/bju.12230 PMID: 23819551